Anciata Therapeutics is a U.S.-based biotechnology company focused on the development of IPX-2017, a novel, potentially first-in-class therapeutic candidate targeting autoimmune disorders. Anciata was created as a special purpose company to advance this orally administered therapy to clinical proof of concept. The company also has the option to collaborate with ExploR&D, a research and development unit within Eli Lilly and Company, for early-stage development services.

Anciata Therapeutics emerges from a strategic partnership between TVM Capital Life Science and Cellestia Biotech AG, leveraging Cellestia’s expertise in immunology and autoimmunity. The company’s scientific approach may also extend benefits beyond autoimmune disorders to patients with allo-immune diseases and cancer, reinforcing its potential impact in areas of high unmet medical need.